Chemotherapy and the Adult Gonad: a Review

Overview

Journal J R Soc Med

Specialty General Medicine

Date 1983 Feb 1

PMID 6338232

Citations 11

Authors

J Waxman

Affiliations

Soon will be listed here.

Citing Articles

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity.

Levi M, Ben-Aharon I, Shalgi R Front Reprod Health. 2022; 4:812053.

PMID: 36303648 PMC: 9580821. DOI: 10.3389/frph.2022.812053.

Melatonin prevents cyclophosphamide-induced primordial follicle loss by inhibiting ovarian granulosa cell apoptosis and maintaining AMH expression.

Feng J, Ma W, Li H, Pei X, Deng S, Jia H Front Endocrinol (Lausanne). 2022; 13:895095.

PMID: 35992124 PMC: 9381702. DOI: 10.3389/fendo.2022.895095.

Ovarian Stem Cells (OSCs) from the Cryopreserved Ovarian Cortex: A Potential for Neo-Oogenesis in Women with Cancer-Treatment Related Infertility: A Case Report and a Review of Literature.

Silvestris E, Minoia C, Guarini A, Opinto G, Negri A, Dellino M Curr Issues Mol Biol. 2022; 44(5):2309-2320.

PMID: 35678686 PMC: 9164018. DOI: 10.3390/cimb44050157.

Female Fertility Preservation through Stem Cell-based Ovarian Tissue Reconstitution In Vitro and Ovarian Regeneration In Vivo.

Akahori T, Woods D, Tilly J Clin Med Insights Reprod Health. 2019; 13:1179558119848007.

PMID: 31191070 PMC: 6540489. DOI: 10.1177/1179558119848007.

Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.

Jang H, Hong K, Choi Y Int J Mol Sci. 2017; 18(6).

PMID: 28590419 PMC: 5486044. DOI: 10.3390/ijms18061221.

References

Sieber S, Correa P, Dalgard D, Adamson R . Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res. 1978; 38(7):2125-34. View

Nillius S, Bergquist C, Wide L . Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?. Contraception. 1978; 17(6):537-45. View

Peters H, Faber M . Morphological study of the ovaries of leukaemic children. Br J Cancer. 1978; 38(1):82-7. PMC: 2009696. DOI: 10.1038/bjc.1978.166. View

Roeser H, Stocks A, Smith A . Testicular damage due to cytotoxic drugs and recovery after cessation of therapy. Aust N Z J Med. 1978; 8(3):250-4. DOI: 10.1111/j.1445-5994.1978.tb04518.x. View

Tcholakian R, De La Cruz A, Chowdhury M, Steinberger A, Coy D, Schally A . Unusual anti-reproductive properties of the analog [d-Leu6,des-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in male rats. Fertil Steril. 1978; 30(5):600-3. View

Bulbrook R, Moore J, Clark G, Wang D, Tong D, HAYWARD J . Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer. Eur J Cancer (1965). 1978; 14(12):1369-75. DOI: 10.1016/0014-2964(78)90120-2. View

Chapman R, Sutcliffe S, Rees L, Edwards C, MALPAS J . Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet. 1979; 1(8111):285-9. DOI: 10.1016/s0140-6736(79)90701-3. View

Bergquist C, Nillius S, Wide L . Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception. 1979; 19(5):497-506. DOI: 10.1016/0010-7824(79)90064-7. View

Fisher B, Sherman B, Rockette H, Redmond C, MARGOLESE R, Fisher E . 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer. 1979; 44(3):847-57. DOI: 10.1002/1097-0142(197909)44:3<847::aid-cncr2820440309>3.0.co;2-3. View

10.

Chapman R, Sutcliffe S, MALPAS J . Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA. 1979; 242(17):1877-81. View

11.

Schulz K, Schmidt-Rhode P, Weymar P, Kunzig H, GEIGER W . The effect of combination chemotherapy on ovarian, hypothalamic and pituitary function in patients with breast cancer. Arch Gynecol. 1979; 227(4):293-301. DOI: 10.1007/BF02109918. View

12.

Brook C, Dombey S . Induction of puberty: long-term treatment with high-dose LHRH. Clin Endocrinol (Oxf). 1979; 11(1):81-7. DOI: 10.1111/j.1365-2265.1979.tb03049.x. View

13.

Fraser H, Laird N, Blakeley D . Decreased pituitary responsiveness and inhibition of the luteinizing hormone surge and ovulation in the stumptailed monkey (Macaca arctoides) by chronic treatment with an agonist of luteinizing hormone-releasing hormone. Endocrinology. 1980; 106(2):452-7. DOI: 10.1210/endo-106-2-452. View

14.

Sanger W, Armitage J, Schmidt M . Feasibility of semen cryopreservation in patients with malignant disease. JAMA. 1980; 244(8):789-90. View

15.

Bonadonna G, Valagussa P . Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304(1):10-5. DOI: 10.1056/NEJM198101013040103. View

16.

Rose D, Davis T . Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980; 40(11):4043-7. View

17.

Chapman R, Sutcliffe S, MALPAS J . Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA. 1981; 245(13):1323-8. View

18.

Glode L, Robinson J, Gould S . Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981; 1(8230):1132-4. DOI: 10.1016/s0140-6736(81)92301-1. View

19.

Shalet S, Hann I, Lendon M, Morris Jones P, Beardwell C . Testicular function after combination chemotherapy in childhood for acute lymphoblastic leukaemia. Arch Dis Child. 1981; 56(4):275-8. PMC: 1627226. DOI: 10.1136/adc.56.4.275. View

20.

Linde R, Doelle G, Alexander N, Kirchner F, Vale W, Rivier J . Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981; 305(12):663-7. DOI: 10.1056/NEJM198109173051203. View